SK Life Science LinX Opens

"Beyond a Shared Office, a Hub for Mutual Growth"

SK Biopharmaceuticals announced on June 8 that it had opened an open innovation space called "SK Life Science LinX" within its U.S. subsidiary, SK Life Science, located in New Jersey on June 5 (local time).


LinX is expected to serve as a "K-Bio bridge," organically connecting Asia's outstanding research and development (R&D) capabilities with the advanced markets and expertise of North America, thereby enhancing global value. At the opening ceremony, a tripartite memorandum of understanding (MOU) was signed between SK Biopharmaceuticals, Korea Trade-Investment Promotion Agency (KOTRA), and the Korean American Society in Biotech and Pharmaceuticals (KASBP) New Jersey/New York Chapter, affirming their mutual cooperation.

SK Biopharm opened 'SK Life Science LinX' on the 5th (local time) to support the entry of promising Korean pharmaceutical and bio companies into the US market and their local growth. From the left: Hyuncheol Kim, Head of the US Branch of the Korea Health Industry Development Institute; Jeongjun Yu, Vice Chairman of SK Inc. and CEO of SK Americas; Minseok Kang, Chairman of KASBP New Jersey/New York chapter; Donghoon Lee, CEO of SK Biopharm; Rakkon Kim, Head of KOTRA New York Trade Center; Sangho Kim, Consul General at the Korean Consulate in New York; Yonggeun Kim, Professor at Hallym University and host at Station C.

SK Biopharm opened 'SK Life Science LinX' on the 5th (local time) to support the entry of promising Korean pharmaceutical and bio companies into the US market and their local growth. From the left: Hyuncheol Kim, Head of the US Branch of the Korea Health Industry Development Institute; Jeongjun Yu, Vice Chairman of SK Inc. and CEO of SK Americas; Minseok Kang, Chairman of KASBP New Jersey/New York chapter; Donghoon Lee, CEO of SK Biopharm; Rakkon Kim, Head of KOTRA New York Trade Center; Sangho Kim, Consul General at the Korean Consulate in New York; Yonggeun Kim, Professor at Hallym University and host at Station C.

View original image

At LinX, the "K-Bio Global Innovation LinX" program, which is part of a bio consortium led by KOTRA, will be operated. Station C, a regional startup brand run by the Korea Health Industry Development Institute and Hallym University, has confirmed its participation, and discussions are underway with other Korean institutions to join as well.


The consortium plans to offer a range of specialized programs to support the early settlement of Korean companies in the United States, such as local settlement assistance, legal and patent consulting, and connections to local investors. The KASBP New Jersey/New York Chapter will host academic symposiums and seminars at LinX, helping to expand networking opportunities with local experts.


SK Biopharmaceuticals stated, "The opening of LinX is highly meaningful as a global case of mutual growth, directly realizing the ESG (Environmental, Social, and Governance) philosophy that SK Biopharmaceuticals has emphasized, by supporting innovation and growth in the K-Bio ecosystem in the United States."



Donghoon Lee, CEO of SK Biopharmaceuticals, commented, "SK Life Science LinX goes beyond a simple shared office to become a hub for mutual growth, driving the development of promising Korean bio companies so that they can stand out on the global stage. Through multifaceted open innovation with leading domestic biotech firms, we will organically combine innovative technologies and resources, solidifying a sustainable, mutually beneficial ecosystem that produces tangible results in the global market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing